
                                SEQUENCE LISTING

<110> UNIVERSITE LAVAL
           
<120> ANTI-S100A8 FOR TREATING LEUKEMIA
  
<130> 05006013-408PCT

<150> US 62/218,000      
<151> 2015-09-14 

<150> US 62/259,738      
<151> 2015-11-25 

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 93
<212> PRT
<213> Human

<220> 
<223> S100A8

<400> 1
Met Leu Thr Glu Leu Glu Lys Ala Leu Asn Ser Ile Ile Asp Val Tyr
 1               5                  10                  15      
His Lys Tyr Ser Leu Ile Lys Gly Asn Phe His Ala Val Tyr Arg Asp
            20                  25                  30          
Asp Leu Lys Lys Leu Leu Glu Thr Glu Cys Pro Gln Tyr Ile Arg Lys
        35                  40                  45              
Lys Gly Ala Asp Val Trp Phe Lys Glu Leu Asp Ile Asn Thr Asp Gly
    50                  55                  60                  
Ala Val Asn Phe Gln Glu Phe Leu Ile Leu Val Ile Lys Met Gly Val
65                  70                  75                  80  
Ala Ala His Lys Lys Ser His Glu Glu Ser His Lys Glu
                85                  90              


<210> 2
<211> 279
<212> DNA
<213> Human

<220> 
<223> S100A8

<400> 2
atgttgaccg agctggagaa agccttgaac tctatcatcg acgtctacca caagtactcc 60
ctgataaagg ggaatttcca tgccgtctac agggatgacc tgaagaaatt gctagagacc 120
gagtgtcctc agtatatcag gaaaaagggt gcagacgtct ggttcaaaga gttggatatc 180
aacactgatg gtgcagttaa cttccaggag ttcctcattc tggtgataaa gatgggcgtg 240
gcagcccaca aaaaaagcca tgaagaaagc cacaaagag                        279

<210> 3
<211> 408
<212> DNA
<213> Artificial Sequence

<220> 
<223> heavy chain variable region of anti-S100A8

<400> 3
ggatcccagg ttcagctgca gcagtcaggg gcagagcttg tgaagccagg ggcctcagtc 60
aagttgtcct gcacagcttc tggcttcaac attaaagaca cctatttgca ctgggtgaag 120
cagaggcctg agcagggcct ggagtgggtt ggaaggattg atcctgcgaa tggtgatact 180
aaatatgacc cgaagttcca ggccaaggcc actataacag ctgacacaac ctccaacaca 240
gcctacgtgc acctcaacag cctgacatct gaggacactg ccgtctattt ctgtactggg 300
ggatggcaga tggggggccg gtacttcgat gtctggggcg cagggacaac ggtcaccgtc 360
tcctcagcca aaacgacacc cccatctgtc tatggtggcg gtggttct              408

<210> 4
<211> 136
<212> PRT
<213> Artificial Sequence

<220> 
<223> heavy chain variable region of anti-S100A8

<400> 4
Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro
 1               5                  10                  15      
Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys
            20                  25                  30          
Asp Thr Tyr Leu His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu
        35                  40                  45              
Trp Val Gly Arg Ile Asp Pro Ala Asn Gly Asp Thr Lys Tyr Asp Pro
    50                  55                  60                  
Lys Phe Gln Ala Lys Ala Thr Ile Thr Ala Asp Thr Thr Ser Asn Thr
65                  70                  75                  80  
Ala Tyr Val His Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
                85                  90                  95      
Phe Cys Thr Gly Gly Trp Gln Met Gly Gly Arg Tyr Phe Asp Val Trp
            100                 105                 110         
Gly Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro
        115                 120                 125             
Ser Val Tyr Gly Gly Gly Gly Ser
    130                 135     


<210> 5
<211> 327
<212> DNA
<213> Artificial Sequence

<220> 
<223> light chain variable region of anti-S100A8

<400> 5
gatgttgtga tgacccagtc tcctgcttcc ttagctgtat ctctggggca gagggccacc 60
atctcataca gggccagcaa aagtgtcagt acatctggct atagttatat gcactggaac 120
caacagaaac caggacagcc acccagactc ctcatctatc ttgtatccaa cctagaatct 180
ggggtccctg ccaggttcag tggcagtggg tctgggacag acttcaccct caacatccat 240
cctgtggagg aggaggatgc tgcaacctat tactgtcagc acattaggga gcttacacgt 300
tcggaggggg gaccaagctg gaaataa                                     327

<210> 6
<211> 108
<212> PRT
<213> Artificial Sequence

<220> 
<223> light chain variable region of anti-S100A8

<400> 6
Asp Val Val Met Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
 1               5                  10                  15      
Gln Arg Ala Thr Ile Ser Tyr Arg Ala Ser Lys Ser Val Ser Thr Ser
            20                  25                  30          
Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro Gly Gln Pro Pro
        35                  40                  45              
Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser Gly Val Pro Ala
    50                  55                  60                  
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65                  70                  75                  80  
Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ile Arg
                85                  90                  95      
Glu Leu Thr Arg Ser Glu Gly Gly Pro Ser Trp Lys
            100                 105             

<210> 7
<211> 114
<212> PRT
<213> Human

<220> 
<223> S100A9

<400> 7
Met Thr Cys Lys Met Ser Gln Leu Glu Arg Asn Ile Glu Thr Ile Ile
 1               5                  10                  15      
Asn Thr Phe His Gln Tyr Ser Val Lys Leu Gly His Pro Asp Thr Leu
            20                  25                  30          
Asn Gln Gly Glu Phe Lys Glu Leu Val Arg Lys Asp Leu Gln Asn Phe
        35                  40                  45              
Leu Lys Lys Glu Asn Lys Asn Glu Lys Val Ile Glu His Ile Met Glu
    50                  55                  60                  
Asp Leu Asp Thr Asn Ala Asp Lys Gln Leu Ser Phe Glu Glu Phe Ile
65                  70                  75                  80  
Met Leu Met Ala Arg Leu Thr Trp Ala Ser His Glu Lys Met His Glu
                85                  90                  95      
Gly Asp Glu Gly Pro Gly His His His Lys Pro Gly Leu Gly Glu Gly
            100                 105                 110         
Thr Pro
        



